India is set to complete 50 new greenfield pharma manufacturing plants in the next two years under its Production-linked Incentive (PLI) scheme for pharma and medical devices. 30 September 2024
The number of clinical trials of new drugs in Russia is steadily declining, which could be mainly related with the overall reduction of investment activities in the local pharmaceutical market, reports The Pharma Letter’s local correspondent. 30 September 2024
Pharmaceutical laboratories, institutions, guilds and medical federations have taken on the task of designing programs to end health illiteracy in order to have informed, educated, knowledgeable and empowered communities where their health and wellbeing are concerned. 19 September 2024
Oligonucleotide therapeutics are rapidly emerging as a promising class of drugs capable of addressing a variety of genetic and complex diseases by targeting RNA sequences.1 16 September 2024
The protection of intellectual property (IP) rights of foreign pharmaceutical companies in Russia remains complex situation, according to recent statements by Konstantin Panurovsky, legal director of AstraZeneca’s Russian subsidiary, reports The Pharma Letter’s local correspondent. 13 September 2024
The Russian Ministry of Health wants to speed registration of drugs that are not localized in the Russian Federation at the time of the application submitted by domestic pharmaceutical companies, explaining such changes by "unpredictable geopolitical situation," reports The Pharma Letter’s local correspondent. 12 September 2024
NewCo, a relatively new business model that involves a joint venture (JV) between a biotech and a group of investors to bring the biotech’s promising assets to the global market, is gaining popularity among Chinese biotechs, who traditionally rely on out-licensing deals to capitalize assets, s 11 September 2024
A significant drop has been noticed in the prices of active pharmaceutical ingredients (APIs), bringing much-needed relief to the pharmaceutical industry and potentially translating to lower drug costs for consumers. 9 September 2024
Targeted alpha therapy (TAT), or radioligand therapy, is a recent hot area that attracted big pharmas like Bristol Myers Squibb and Novartis. 5 September 2024
German pharma major Bayer has filed a lawsuit against the Russian drugmaker Promomed to protect the patent rights for Xarelto (rivaroxaban), its treatment for stroke prevention which is the best-selling drug in the Russian market at present, The Pharma Letter’s local correspondent reports. 2 September 2024
Scientists from the Russian Institute of Immunology of the Federal Medical and Biological Agency (FMBA) say they have created the world's first allergy vaccine. 30 August 2024
In a major crackdown, the Indian government has imposed an immediate ban on 156 fixed-dose combination (FDC) drugs, including commonly used antibiotics, pain relievers,and multivitamins. 27 August 2024
Russia plans to create conditions for a significant increase of domestic production of anti-Rhesus immunoglobulin drugs after a sharp decrease of their imports to the local market this year, reports The Pharma Letter’s local correspondent. 22 August 2024
One of the largest pharmaceutical production facilities in the Russian North-West region will soon be built in the city of Pushkino by the local drugmaker Active Component enterprise, The Pharma Letter’s local correspondent reports. 14 August 2024
The shortage of drugs in Russia is deepening, and is currently being observed in almost 70 regions throughout the country and forcing the local state to consider ways to resume stable supplies to local market, reports The Pharma Letter’s local correspondent. 13 August 2024
The Russian Ministry of Health has registered the third Russian generic of the original drug Ozempic (semaglutide) from Danish drugmaker Novo Nordisk. 8 August 2024
US biotech major Biogen is disputing the launch of a Russian generic of Spinraza (nusinersen), a drug, which is used to treat spinal muscular atrophy (SMA), reports The Pharma Letter’s local correspondent. 7 August 2024
Domestic drugs and foreign drugs, the production of which is localized in Russia, will be given a priority when included in the list of vital and essential drugs (VED) and expensive drugs, according to a recent resolution signed by the Russian government, The Pharma Letter’s local correspondent reports. 1 August 2024
Major pharmaceutical multinationals are looking to collaborate with Indian drug firms, leveraging their cost-efficient manufacturing capabilities, robust supply chains, and innovative research potential. 31 July 2024
The Russian government will be ready to significantly increase state procurements of drugs against hepatitis C in case of reduction price for them both by global drugmakers and Russian pharmaceutical companies. 31 July 2024
The month of July celebrated World Sjögren's Day, dedicated to Sjögren's syndrome (SS) – a condition affecting between 0.5% and 1% of the population.1 30 July 2024
The US Food and Drug Administration’s (FDA) Office of New Drugs (OND), part of the Center for Drug Evaluation and Research (CDER), plays a pivotal role in advancing public health by facilitating access to novel, effective and safe drugs that address unmet clinical needs. 29 July 2024
“Circle of Goodness,” one of Russia’s largest public funds, specializing on procurements of drugs for children with rare diseases, will begin procurements of the US drug Vyjuvek (beremagen heperpavec), which is designed for patients with epidermolysis bullosa (butterfly syndrome), reports The Pharma Letter’s local correspondent. 25 July 2024
60% of listed Indian pharmaceutical companies have experienced an uptick in new business inquiries from US pharma companies due to the discussions around the US Biosecure Act. 18 July 2024
Russian drugmaker Promomed is aiming to accelerate expansion in both domestic and foreign markets in the coming years, reports The Pharma Letter’s local correspondent. 18 July 2024
Trade association has called on the authorities of Russia to make adjustments for the methods of calculation of the initial maximum price of contracts (IMCP) for public procurements of drugs. 17 July 2024
The Russian drugmaker Geropharm has demanded a compulsory license from Denmark’s Novo Nordisk to produce a generic of Ozempic (semaglutide), which is a drug used for diabetes and the active ingredient is marketed as Wegovy for weight loss, reports The Pharma Letter’s local correspondent. 12 July 2024
GlaxoSmithKline Trading, the distribution division of the British pharma major GSK, has filed a complaint to the Russian anti-trust regulator FAS on the recent auction for state procurements of GSK’s anti-HIV drug Tivicay (dolutegravir). 12 July 2024
Latin American countries have taken on the task of exploring how a tool such as regulatory reliance can be better used to improve health ecosystems in the region, based on trust and teamwork, without having to complete their own thorough reviews that demand time and resources. 1 July 2024
India's Production Linked Incentive (PLI) scheme has struck gold with the inclusion of semaglutide, a key GLP-1 receptor agonist used in the treatment of diabetes and obesity. 30 June 2024
Russia will speed up the process of launching generics of original drugs that have been withdrawn from the market by their producers in a move to ensure better security of the country in its pharmaceutical sector, reports The Pharma Letter’s local correspondent. 25 June 2024
The Swiss company Swixx BioPharma has stopped the supplies of Humalog insulin (insulin lispro) to Russia due to the decision of its manufacturer, the American pharma major Eli Lilly, The Pharma Letter’s local correspondent reports. 19 June 2024
The Russian pharmaceutical market is undergoing a large-scale transformation, as the share of foreign drugs is steadily declining due to acceleration of processes of import substitution, reports The Pharma Letter’s local correspondent. 18 June 2024
The recent US crackdown on Chinese biotech companies marks a significant shift in the global biotechnology landscape, with profound implications for competitive strategies. 18 June 2024
Russia is sharply cutting centralized state purchases of anti-HIV drugs due to the problems with funding and the reduction of supplies to Russia by global drugmakers, reports The Pharma Letter’s local correspondent. 12 June 2024
Indian generics drugmaker Cadila Pharmaceuticals, together with the Russian investment fund the Russian Direct Investment Fund (RDIF), will invest more than 10 billion roubles ($112 million) in the establishment of a pharmaceutical complex and an injection drug plant in Russia. 11 June 2024
Russian drugmaker Nanolek plans to accelerate its expansion this year by expanding its range and increase of output, paying a particular focus to vaccines, The Pharma Letter’s local correspondent reports. 5 June 2024
India has become the largest supplier of drugs to the Russian market, overtaking Germany, which had been in the lead for the last two years, reports The Pharma Letter’s Russia correspondent. 4 June 2024
Russia has suspended state purchases of a number of original anti-cancer drugs due to problems associated with sanctions and the ever-growing isolation of the country in the international arena, The Pharma Letter’s local correspondent reports. 29 May 2024
The drug shortage crisis in the USA, intensified by supply chain disruptions and increased demand, presents a significant opportunity for Indian pharmaceutical companies to offer essential support. 28 May 2024